Does prior immunization with measles, mumps, and rubella vaccines contribute to the antibody response to COVID-19 antigens?

Does prior immunization with measles, mumps, and rubella vaccines contribute to the antibody response to COVID-19 antigens?

Background: Incidence and severity of SARS-CoV2 infection are significantly lower in children and teenagers proposing that certain vaccines, routinely administered to neonates and children may provide cross-protection against this emerging infection. Objective: To assess the cross-protection induc...

Full description

Bibliographic Details
Main Authors:	Danesh Hassani, Mohammad Mehdi Amiri, Faezeh Maghsood, Vahid Salimi, Gholam Ali Kardar, Omid Barati, Seyed Mohammad Reza Hashemian, Mahmood Jeddi-Tehrani, Amir-Hassan Zarnani, Fazel Shokri
Format:	Article
Language:	English
Published:	Shiraz University of Medical Sciences 2021-03-01
Series:	Iranian Journal of Immunology
Subjects:	antibody response cross-protection mmr sars-cov2 tetanus
Online Access:	https://iji.sums.ac.ir/article_47467_2866f9f848db52c513482a08052f27a2.pdf

Similar Items

Hubungan vaksin Measles, Mumps, Rubella (MMR) dengan Kejadian Autisme
by: Elsye Souvriyanti, et al.
Published: (2016-12-01)

Safety of measles, mumps, and rubella vaccine in adolescents and adults in the vaccine safety Datalink
by: Kayla E. Hanson, et al.
Published: (2023-04-01)

Anticancer Activity of Measles–Mumps–Rubella MMR Vaccine Viruses against Glioblastoma
by: Zumama Khalid, et al.
Published: (2023-08-01)

Analysis of Measles-Mumps-Rubella (MMR) Titers of Recovered COVID-19 Patients
by: Jeffrey E. Gold, et al.
Published: (2020-12-01)

Association Between Subnational Vaccine Coverage, Migration, and Incident Cases of Measles, Mumps, and Rubella in Iraq, 2001–2016
by: Haley Comfort, et al.
Published: (2022-01-01)

A review of safety and immunogenicity of a novel measles, mumps, rubella (MMR) vaccine
by: Nitin Shah, et al.
Published: (2024-12-01)

Vaksinasi Measles, Mumps, dan Rubella (MMR) Sebagai Prophylaxis Terhadap COVID-19
by: Sajuni Widjaja
Published: (2020-06-01)

Associations of adaptive immune cell subsets with measles, mumps, and Rubella−Specific immune response outcomes
by: Lin Wang, et al.
Published: (2023-12-01)

A Case of Genital and Extragenital Warts Unresponsive to Immunotherapy Using Measles, Mumps, Rubella Vaccine
by: Achdiat PA, et al.
Published: (2023-11-01)

Implementation of the preventive vacc ination program against measles, mumps, and rubella (MMR) on the example of a selected clinic in the city of Krakow
by: Marek Wojczyk, et al.
Published: (2020-06-01)

Mumps vaccine effectiveness of a 3rd dose of measles, mumps, rubella vaccine in school settings during a mumps outbreak -- Arkansas, 2016-2017
by: Angela Guo, et al.
Published: (2023-12-01)

Seroconversion rates following 2 doses of measles- mumps- rubella vaccination given at the ages 12 and 18 months: data for possible additional dose at older age
by: Hana Saffar, et al.
Published: (2022-01-01)

A study to evaluate the role of intradermal and intralesional measles, mumps, rubella (MMR) vaccine in treatment of common warts
by: Pragya Gupta, et al.
Published: (2020-01-01)

Serologic screening and infectious diseases consultation in renal transplant candidates for measles, mumps, rubella and varicella
by: Seckin Zeynep Idil, et al.
Published: (2021-06-01)

Measles and rubella serosusceptibity among population vaccinated with different schedules: the potential impact on measles-rubella elimination in Iran
by: Hana Saffar, et al.
Published: (2021-03-01)

Voluntary termination of pregnancy: An opportunity for Measles, Mumps and Rubella vaccination in an Italian healthcare local unit
by: V. Pettinicchio, et al.
Published: (2018-04-01)

Does Measles, Mumps, and Rubella (MMR) Vaccination Protect against COVID-19 Outcomes: A Nationwide Cohort Study
by: Epiphane Kolla, et al.
Published: (2022-11-01)

Body Mass Index and Antibody Persistence after Measles, Mumps, Rubella and Hepatitis B Vaccinations
by: Marco Fonzo, et al.
Published: (2022-07-01)

Intralesional measles, mumps and rubella vaccine versus formic acid puncture in the treatment of common warts: A prospective randomised study
by: Myfanwy J D'Souza, et al.
Published: (2023-01-01)

Mumps Postexposure Prophylaxis with a Third Dose of Measles-Mumps-Rubella Vaccine, Orange County, New York, USA
by: Amy Parker Fiebelkorn, et al.
Published: (2013-09-01)

Two cases of measles after vaccination with measles mumps and rubella combined live attenuated vaccine
by: SHEN Jinhua, et al.
Published: (2022-05-01)

Effectiveness of Booster Measles-Mumps-Rubella Vaccination in Lower COVID-19 Infection Rates: A Retrospective Cohort Study in Turkish Adults
by: Yengil E, et al.
Published: (2021-05-01)

Clinical trials show similar safety outcomes including febrile convulsion rates for GSK’s and Merck’s measles-mumps-rubella (MMR) vaccines
by: Md Ahsan Habib, et al.
Published: (2023-01-01)

Intralesional measles–mumps–rubella is associated with a higher complete response in cutaneous warts: a systematic review and meta-analysis of randomized controlled trial including GRADE qualification
by: Rachel Vania, et al.
Published: (2021-11-01)

Two-year antibody persistence in children vaccinated at 12–15 months with a measles-mumps-rubella virus vaccine without human serum albumin
by: Andrea A. Berry, et al.
Published: (2017-07-01)

Seroepidemiology of Measles, Mumps and Rubella on Bonaire, St. Eustatius and Saba: The First Population-Based Serosurveillance Study in Caribbean Netherlands
by: Regnerus A. Vos, et al.
Published: (2019-10-01)

Immune response to co-administration of measles, mumps, and rubella (MMR), and yellow fever vaccines: a randomized non-inferiority trial among one-year-old children in Argentina
by: Carla Vizzotti, et al.
Published: (2023-03-01)

Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study
by: The MMR-162 Study Group
Published: (2018-12-01)

Antibody Levels at 3-Years Follow-Up of a Third Dose of Measles-Mumps-Rubella Vaccine in Young Adults
by: Patricia Kaaijk, et al.
Published: (2022-01-01)

Measles-mumps-rubella vaccine at 6 months of age, immunology, and childhood morbidity in a high-income setting: study protocol for a randomized controlled trial
by: Dorthe Maria Vittrup, et al.
Published: (2020-12-01)

SINDROM RUBELLA KONGENITAL
by: Julia Fitriany, et al.
Published: (2018-09-01)

Evaluation of the efficacy of intralesional measles, mumps, and rubella vaccine with intralesional Vitamin D3 as immunotherapies in the treatment of recalcitrant cutaneous warts in adult- A randomized placebo-controlled study
by: Alpana Mohta, et al.
Published: (2021-01-01)

Changes in cytokine profile with immunotherapy in viral warts using purified protein derivative, mumps measles rubella vaccine, and mycobacterium w vaccine
by: Amrita Sil, et al.
Published: (2021-01-01)

Immunogenicity and safety of the new MMR vaccine containing measles AIK-C, rubella Takahashi, and mumps RIT4385 strains in Japanese children: a randomized phase I/II clinical trial
by: Tetsuo Nakayama, et al.
Published: (2019-05-01)

Epidemiological changes in mumps infections between 1990 and 2017 in urban area of Shanghai, China
by: Hong Pang, et al.
Published: (2021-05-01)

Difficulties in eliminating measles and controlling rubella and mumps: a cross-sectional study of a first measles and rubella vaccination and a second measles, mumps, and rubella vaccination.
by: Zhifang Wang, et al.
Published: (2014-01-01)

Response to third rubella vaccine dose
by: Lotta Siira, et al.
Published: (2018-10-01)

Longitudinal Characterization of the Mumps-Specific HLA-A2 Restricted T-Cell Response after Mumps Virus Infection
by: Josien Lanfermeijer, et al.
Published: (2021-12-01)

TIMELINESS AND LEVEL OF PRIMARY IMMUNIZATION COVERAGE AGAINST MEASLES AND RUBELLA IN MONTENEGRO
by: Branislav Tiodorović, et al.
Published: (2009-10-01)

Seroprevalence of measles, mumps, and rubella and genetic characterization of mumps virus in Khartoum, Sudan
by: Omer Adam, et al.
Published: (2020-02-01)